Articles tagged with: Kyprolis
NewsFlash »
Onyx Pharmaceuticals Initiates Phase 3 Myeloma Trial Of Carfilzomib – Onyx Pharmaceuticals on Wednesday announced the start of enrollment for an international Phase 3 trial of carfilzomib in relapsed/refractory multiple myeloma patients. The trial will enroll 700 patients and will test carfilzomib in combination with Revlimid (lenalidomide) and low-dose dexamethasone (Decadron) versus Revlimid and low-dose dexamethasone without carfilzomib. Carfilzomib is a proteasome inhibitor that prevents the growth and spread of myeloma cells by interrupting their protein-related cellular processes. For more information, please see the Onyx Pharmaceuticals press release and the clinical trial description.
EntreMed’s ENMD-2076 Shows Anti-Myeloma Activity – EntreMed announced last week that its new cancer compound ENMD-2076 showed significant anti-myeloma activity in pre-clinical studies. EntreMed has already launched a Phase 1 study in multiple myeloma patients. ENMD-2076 prevents the growth and spread of myeloma cells by interfering with cell division. For more information, please see the EntreMed press release and the clinical trial description.
IMF Will Hold Myeloma Patient & Family Seminar – The International Myeloma Foundation (IMF) will be holding a seminar for myeloma patients and their families August 13 to 14 in Philadelphia, PA. Myeloma experts Dr. Brian Durie and Dr. Robert Kyle are among the speakers scheduled to present during Saturday’s general session. The cost for the seminar is $60 per person. For more information or to register, please visit the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
An ongoing Phase 2 trial of carfilzomib has demonstrated that carfilzomib may be effective in treating relapsed/refractory multiple myeloma patients, including patients who are resistant to or relapsed after Velcade (bortezomib) treatment. The results were presented by Dr. Ravi Vij of Washington University in St. Louis at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago on June 5.
“Single agent carfilzomib has demonstrated significant activity in relapsed/refractory myeloma,” said Dr. Vij during his presentation.
Carfilzomib, developed by Onyx Pharmaceuticals, is a new drug currently being investigated …
News»
Yesterday -- Saturday, June 5 -- was the second day of the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago. It was a busy day in terms of research posters and presentations related to multiple myeloma. As a result, there is a lot of ground to cover in this update.
Almost 40 myeloma-related posters were up for meeting attendees to view during the daytime poster session on "lymphoma and plasma cell disorders." Among those 40-or-so posters, six concerned research done by the myeloma team at the University of Arkansas for Medical Sciences (UAMS), …
News»
Friday, June 4, was the first day of this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Most of the big multiple myeloma news of the day came out of a poster session in the afternoon.
At "poster sessions," researchers present a poster-sized summary of their research in a small, 2 meter by 1 meter cubicle. Researchers and physicians mill about, taking pictures of the posters with their cell phone cameras or taking notes. Sometimes one or more of the contributing researchers are present to answer questions. More often than …
Deutsch»
Vorläufige Ergebnisse von einer laufenden Phase I Studie legen nahe, dass Carfilzomib in Kombination mit Revlimid (Lenalidomid) und niedrig dosiertem Dexamethason bei Patienten mit rezidiviertem oder refraktärem Myelom über einen längeren Zeitraum gut verträglich ist. Diese Ergebnisse wurden heute auf dem jährlichen Treffen der American Society of Clinical Oncology (ASCO) in Chicago präsentiert.
Carfilzomib ist ein neues Medikament, welches von Onyx Pharmaceuticals entwickelt und für die Behandlung von Patienten mit refraktärem oder rezidiviertem Myelom untersucht wird. Es hat eine ähnliche Wirkung wie Velcade (Bortezomib), indem es die Beschädigung von Eiweißen …
News»
Preliminary results from an ongoing Phase 1b clinical trial suggest that carfilzomib (Kyprolis) in combination with Revlimid (lenalidomide) and low-dose dexamethasone (Decadron) is well-tolerated over extended periods of therapy in patients who have relapsed or are resistant (refractory) to previous myeloma treatment.
The findings were presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Carfilzomib is a new therapy being developed by Onyx Pharmaceuticals and studied for the treatment of patients with relapsed or refractory myeloma. It works similarly to Velcade (bortezomib) by preventing …
NewsFlash »
LLS Increases Financial Support For Myeloma Patients - As of Feb 1, the Leukemia & Lymphoma Society (LLS) will provide multiple myeloma patients with up to $10,000 to cover insurance-related expenses such as co-payments and insurance premiums. The new limit is an increase from the previous limit of $5,000 and is retroactive for expenses beginning July 1, 2009. For more information or to apply, please see the LLS Co-Pay Assistance Web site.
Carfilzomib Phase 3 Clinical Trial Design Is Approved – Onyx Pharmaceuticals, Inc. announced that it has reached an agreement with the Food and Drug Administration on the design and analysis of a Phase 3 clinical trial evaluating carfilzomib in relapsed myeloma. The study follows up a Phase 1B trial that examined carfilzomib in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) (see related Beacon news). The Phase 3 trial is expected to begin in early to mid 2010, and the Phase 1b/2 study of this combination regimen is still recruiting participants. For more information, please see the Onyx press release.
Cancer Vaccine Produces Positive Results In Multiple Myeloma Patient – Results from a study evaluating the effects of a high dose cancer vaccine in patients with multiple myeloma, myelodysplastic syndromes, and acute myeloid leukemia showed positive immune responses in several patients. The vaccine helps the immune system kill cancer cells by building up antibodies to a protein called RHAMM, which is associated with cancer progression. In one of the three myeloma patients, the vaccine led to a decrease of the patient’s free light chains, from 10.3 mg/L to 2.26 mg/L. Side effects were limited to mild redness and infection of the skin. For more information, please see the journal Haematologica (pdf).
